{"id":3822,"date":"2019-06-10T06:54:15","date_gmt":"2019-06-10T06:54:15","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/"},"modified":"2019-06-10T06:54:15","modified_gmt":"2019-06-10T06:54:15","slug":"nanexas-pharmashell-patent-godkant-i-japan","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/","title":{"rendered":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan"},"content":{"rendered":"
\n

<\/strong><\/span><\/p>\n<\/div>\n

Japanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae.<\/span><\/p>\n

Nanexas drug delivery-system PharmaShell\u00ae\u00a0\u00e4r avpassad f\u00f6r parenteral administrering av l\u00e4kemedel. Drug delivery-systemet m\u00f6jligg\u00f6r fris\u00e4ttning av l\u00e4kemedel p\u00e5 ett v\u00e4lkontrollerat s\u00e4tt fr\u00e5n ett par veckor till riktigt l\u00e5nga dep\u00e5tider p\u00e5 upp till ett \u00e5r. Dep\u00e5tiden kan, genom justeringar i tillverkningsprocessen av PharmaShell\u00ae, styras till \u00f6nskad l\u00e4ngd.<\/span><\/p>\n

PharmaShells\u00ae\u00a0egenskaper, med extremt h\u00f6g s\u00e5 kallad drug load och m\u00f6jlighet att styra den initiala fris\u00e4ttningen, g\u00f6r den unik p\u00e5 marknaden. Systemet m\u00f6jligg\u00f6r dep\u00e5beredningar av alltfr\u00e5n enkla sm\u00e5molekyl\u00e4ra l\u00e4kemedel till proteiner. De n\u00e4mnda egenskaperna \u00e4r efterfr\u00e5gade av l\u00e4kemedelsindustrin f\u00f6r att skapa nya och mer effektiva l\u00e4kemedel med m\u00f6jlighet att begr\u00e4nsa l\u00e4kemedlets biverkningar.<\/span><\/p>\n

Det japanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan den 30 maj 2019. Det nu godk\u00e4nda patentet t\u00e4cker in sj\u00e4lva produkten PharmaShell\u00ae\u00a0samt metoden f\u00f6r dess tillverkning och formuleringar av PharmaShell\u00ae-belagda l\u00e4kemedel. Det godk\u00e4nda patentet har patentnummer JP6516729.<\/span><\/p>\n

F\u00f6retagets VD David Westberg kommenterar:<\/span><\/p>\n

I januari fock vi PharmaShell\u00ae-patentet godk\u00e4nt i USA och jag kan nu konstatera att det \u00e4ven har godk\u00e4nts i Japan. Den japanska marknaden \u00e4r stor och viktig f\u00f6r Nanexa och med en godk\u00e4nd patentans\u00f6kan \u00f6kar v\u00e5ra kommersiella m\u00f6jligheter i framtiden.<\/span><\/p>\n

V\u00e5rt kontinuerliga arbete med patentans\u00f6kningarna b\u00f6rjar ge resultat och tillsammans med v\u00e5ra mer nyligt inl\u00e4mnade patentans\u00f6kningar bed\u00f6mmer jag att vi har en stark patentportf\u00f6lj.<\/span><\/p>\n

F\u00f6r mer information kontakta:
David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ) Telefon: 0709 -42 83 03
E-post:\u00a0david.westberg@nanexa.sewww.nanexa.com<\/span><\/p>\n

Om Nanexa AB (publ)<\/span><\/p>\n

Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00aesom \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00aehar Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

Read as PDF<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n

Japanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae.<\/p>\n

Nanexas drug delivery-system PharmaShell\u00ae\u00a0\u00e4r avpassad f\u00f6r parenteral administrering av l\u00e4kemedel. Drug delivery-systemet m\u00f6jligg\u00f6r fris\u00e4ttning av l\u00e4kemedel p\u00e5 ett v\u00e4lkontrollerat s\u00e4tt fr\u00e5n ett par veckor till riktigt l\u00e5nga dep\u00e5tider p\u00e5 upp till ett \u00e5r.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3822","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Japanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae. Nanexas drug delivery-system PharmaShell\u00ae\u00a0\u00e4r avpassad f\u00f6r parenteral administrering av l\u00e4kemedel. Drug delivery-systemet m\u00f6jligg\u00f6r fris\u00e4ttning av l\u00e4kemedel p\u00e5 ett v\u00e4lkontrollerat s\u00e4tt fr\u00e5n ett par veckor till riktigt l\u00e5nga dep\u00e5tider p\u00e5 upp till ett \u00e5r.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-japan\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-japan\\\/\",\"name\":\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-06-10T06:54:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-japan\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-japan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-japan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB","og_description":"Japanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae. Nanexas drug delivery-system PharmaShell\u00ae\u00a0\u00e4r avpassad f\u00f6r parenteral administrering av l\u00e4kemedel. Drug delivery-systemet m\u00f6jligg\u00f6r fris\u00e4ttning av l\u00e4kemedel p\u00e5 ett v\u00e4lkontrollerat s\u00e4tt fr\u00e5n ett par veckor till riktigt l\u00e5nga dep\u00e5tider p\u00e5 upp till ett \u00e5r.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/","name":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-06-10T06:54:15+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-japan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i Japan"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}